BeOne Medicines (ONC) Free Cash Flow (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Free Cash Flow of $158.1 million for Q1 2026, up 1092.51% year-over-year from $13.3 million in Q1 2025, and down 68.9% quarter-over-quarter from $508.4 million in Q4 2025.
BeOne Medicines (ONC) Free Cash Flow (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Free Cash Flow for 12 consecutive years, with $158.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 1092.51% year-over-year to $158.1 million; the TTM figure through Mar 2026 stood at $1.2 billion (up 422.21% YoY), while the FY2025 annual figure was $1.1 billion, up 607.38% from the prior year.
- Free Cash Flow fell to $158.1 million in Q1 2026 per ONC's latest filing, from $508.4 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $508.4 million in Q4 2025 and bottomed at -$707.3 million in Q3 2022.
- Historically, Free Cash Flow has averaged -$120.8 million across 5 years, with a median of -$54.6 million in 2024.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 479.6% — and 2026, when it jumped 1092.51%.
- BeOne Medicines' Free Cash Flow stood at -$439.5 million in 2022, then surged by 53.17% to -$205.8 million in 2023, then soared by 138.95% to $80.2 million in 2024, then soared by 534.18% to $508.4 million in 2025, then sank by 68.9% to $158.1 million in 2026.
- Business Quant data shows ONC's Free Cash Flow at $158.1 million in Q1 2026, $508.4 million in Q4 2025, and $354.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -268.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 437.80 Mn |
| Jun 30, 2026 | 437.80 Mn |
| Mar 31, 2026 | 158.09 Mn |
| Mar 31, 2026 | 158.09 Mn |
| Dec 31, 2025 | 508.38 Mn |
| Dec 31, 2025 | 508.38 Mn |
| Sep 30, 2025 | 354.47 Mn |
| Sep 30, 2025 | 354.47 Mn |
| Jun 30, 2025 | 223.38 Mn |
| Jun 30, 2025 | 223.38 Mn |
| Mar 31, 2025 | -15.93 Mn |
| Mar 31, 2025 | -15.93 Mn |
| Dec 31, 2024 | 80.16 Mn |
| Dec 31, 2024 | 80.16 Mn |
| Sep 30, 2024 | 228.62 Mn |
| Sep 30, 2024 | 228.62 Mn |
| Jun 30, 2024 | -54.57 Mn |
| Jun 30, 2024 | -54.57 Mn |
| Mar 31, 2024 | -465.15 Mn |
| Mar 31, 2024 | -465.15 Mn |